GO:0033624 negative regulation of integrin activation: Signaling Checkpoint, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0033624 describes any process that stops, prevents, or reduces the frequency, rate, or extent of integrin activation, a key checkpoint in cell adhesion and signaling.
• Negative regulators of integrin activity include phosphatases such as TCPTP, which directly counteract integrin-mediated signaling.
• Integrin activation is tightly controlled to prevent inappropriate platelet aggregation, immune cell activation, and cancer progression.
• Dysregulation of negative regulation of integrin activation contributes to thrombosis, autoimmune diseases, and tumor metastasis.
• Key genes involved include ITGA1, ITGB1, PTPN2, and others that modulate integrin affinity and downstream signaling.
• CRISPR-based knockout, knock-in, and overexpression models are essential to dissect the causal roles of these regulators in disease.
Description
Integrins are heterodimeric cell surface receptors that mediate cell-cell and cell-extracellular matrix adhesion, and their activation state is critical for processes such as immune responses, platelet aggregation, and tissue repair. The term GO:0033624, negative regulation of integrin activation, refers to any process that stops, prevents, or reduces the frequency, rate, or extent of integrin activation. This regulatory mechanism ensures that integrins remain in a low-affinity state until appropriate signals trigger conformational changes that enable ligand binding. Negative regulation is essential to avoid aberrant adhesion that can lead to pathological conditions including thrombosis, inflammation, and cancer metastasis. Research into this process has identified multiple negative regulators, such as protein tyrosine phosphatases and redox-sensitive pathways, that directly modulate integrin function. Understanding these mechanisms is vital for developing targeted therapies that can restore normal integrin regulation in disease.
negative regulation of integrin activation At A Glance
| GO ID | GO:0033624 |
|---|---|
| GO term | negative regulation of integrin activation |
| Ontology | biological_process |
| Synonym | negative regulation of integrin complex activation |
| Major function | Suppresses integrin conformational activation to maintain low-affinity state |
| Related processes | Cell adhesion, platelet activation, immune cell signaling |
| Key regulators | Protein tyrosine phosphatases (e.g., TCPTP), redox modulators |
| Disease relevance | Thrombosis, cancer metastasis, autoimmune disorders |
What Is GO:0033624?
GO:0033624 is defined as any biological process that stops, prevents, or reduces the frequency, rate, or extent of integrin activation. Integrin activation involves a conformational change from a low-affinity to a high-affinity state, allowing binding to ligands such as fibronectin or fibrinogen. Negative regulation of this process can occur through direct interaction with integrin cytoplasmic tails, modulation of signaling pathways that control integrin affinity, or changes in the cellular redox environment.
Why Is negative regulation of integrin activation Important in Cell Biology?
Negative regulation of integrin activation is a fundamental checkpoint that prevents inappropriate cell adhesion and signaling, which is crucial for normal physiology and for avoiding pathological conditions such as thrombosis, chronic inflammation, and cancer progression. Dysregulation of this process can lead to uncontrolled platelet aggregation or immune cell infiltration, making it a therapeutic target.
• Prevents spontaneous platelet aggregation and thrombosis by keeping integrins inactive until needed.
• Controls immune cell trafficking and activation, preventing autoimmune responses.
• Limits cancer cell adhesion and metastasis by counteracting integrin-mediated survival signals.
• Maintains tissue homeostasis by regulating cell-ECM interactions.
• Involved in redox signaling, linking oxidative stress to integrin function.
• Provides targets for anti-thrombotic and anti-metastatic therapies.
• Essential for proper development and wound healing.
• Modulates integrin crosstalk with growth factor receptors like EGFR.
What Happens During negative regulation of integrin activation?
Initiation of negative regulation
In simple terms: The cell receives signals that tell integrins to stay inactive.
Negative regulation of integrin activation begins when intracellular or extracellular cues trigger pathways that maintain integrins in a low-affinity conformation. This can involve phosphatases that dephosphorylate key signaling molecules, or proteins that bind directly to integrin cytoplasmic tails and stabilize the inactive state.
Direct modulation of integrin affinity
In simple terms: Proteins interact with integrins to keep them folded in an inactive shape.
Negative regulators such as protein tyrosine phosphatases (e.g., TCPTP) can directly interact with integrin-associated signaling complexes, reversing activating phosphorylations and preventing talin binding, which is required for integrin activation. Redox-dependent mechanisms can also modify integrin function by altering disulfide bonds or cysteine residues.
Signaling crosstalk with growth factor receptors
In simple terms: Integrins talk to other receptors to dampen activation signals.
Integrin α1β1 can activate protein tyrosine phosphatase TCPTP, which in turn negatively regulates EGFR signaling, demonstrating crosstalk that indirectly suppresses integrin activation pathways. This crosstalk ensures that adhesion and growth factor signaling are coordinated.
Maintenance of low-affinity state
In simple terms: The cell keeps integrins inactive until a specific trigger arrives.
Sustained negative regulation involves continuous activity of phosphatases and other inhibitory proteins that keep integrins in a bent, low-affinity conformation. This prevents spontaneous ligand binding and downstream signaling, which is critical for circulating platelets and resting immune cells.
Reversal upon activation signals
In simple terms: When needed, the brakes are released and integrins can activate.
Negative regulation is reversible; upon appropriate stimulation (e.g., chemokines or thrombin), activating signals overcome inhibitory pathways, allowing talin and kindlin to bind integrin tails and induce conformational activation. This dynamic balance is essential for timely adhesion.
Key Genes Involved in GO:0033624 negative regulation of integrin activation
The following genes and proteins are key players in negative regulation of integrin activation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTPN2 (TCPTP) | Protein tyrosine phosphatase that dephosphorylates signaling molecules to suppress integrin activation | Direct negative regulator; knockout leads to increased integrin activity |
| ITGA1 | Integrin alpha-1 subunit; forms α1β1 heterodimer that activates TCPTP | Mediates negative regulation of EGFR and integrin crosstalk |
| ITGB1 | Integrin beta-1 subunit; common partner for many alpha subunits | Central to integrin activation; target for negative regulation |
| ITGA5 | Integrin alpha-5 subunit; forms α5β1 fibronectin receptor | Involved in cancer progression; negative regulators modulate its activity |
| ITGAV | Integrin alpha-V subunit; forms αvβ6 with beta-6 | Plays role in TGF-beta activation and immune evasion |
| ITGB6 | Integrin beta-6 subunit; partners with αv | Targeted in cancer; negative regulation affects its pro-tumorigenic signaling |
| FERMT2 (Kindlin-2) | Activator of integrins; negative regulators may oppose its function | Potential target for modulating integrin activation |
| TLN1 (Talin-1) | Key activator of integrins; negative regulators prevent its binding | Central node for negative regulation |
| PTK2 (FAK) | Focal adhesion kinase; downstream of integrin activation | Negative regulators reduce FAK phosphorylation |
| SRC | Non-receptor tyrosine kinase; involved in integrin signaling | Negatively regulated by phosphatases |
| EGFR | Growth factor receptor; crosstalk with integrins | Negatively regulated by integrin-TCPTP axis |
| EPHB2 | Ephrin receptor; redox regulation of integrin crosstalk | Involved in ephrin/integrin cross-talk |
| PTPN11 (SHP2) | Phosphatase that can modulate integrin signaling | Potential negative regulator in platelets |
| RAP1A | Small GTPase; promotes integrin activation | Negative regulators may inhibit RAP1A |
| RAP1GAP | GTPase-activating protein for RAP1; inactivates RAP1 | Indirect negative regulator of integrin activation |
| DOK1 | Docking protein; recruits negative regulators | Modulates integrin signaling in immune cells |
| PECAM1 | Adhesion molecule; can inhibit integrin activation | Involved in platelet and leukocyte regulation |
| CD47 | Integrin-associated protein; signals to inhibit integrin function | Negative regulator in platelets and immune cells |
How Is negative regulation of integrin activation Regulated?
Negative regulation of integrin activation is itself tightly controlled by various signaling pathways. For example, protein tyrosine phosphatases such as TCPTP are regulated by redox state and can be activated by integrin α1β1 engagement. In platelets, negative regulators like PECAM1 and CD47 are modulated by shear stress and soluble agonists to prevent inappropriate aggregation. Additionally, crosstalk with growth factor receptors like EGFR can influence the balance between activating and inhibitory signals.
negative regulation of integrin activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ITGB6 | Triple-negative breast cancer, immune evasion | Knockout in TNBC cell lines; xenograft models |
| ITGA5 | TNBC progression via FAK/PI3K/AKT | Overexpression and knockout in breast cancer cells |
| PTPN2 | Cancer, autoimmunity; negative regulator of integrin signaling | Knockout mice; cell-based assays |
| PECAM1 | Thrombosis, platelet dysfunction | Platelet-specific knockout models |
| CD47 | Thrombosis, immune evasion | Knockout mice; platelet function tests |
Cancer progression and metastasis
Loss of negative regulation of integrin activation can lead to increased integrin activity, promoting cancer cell adhesion, migration, and metastasis. In triple-negative breast cancer, integrin αvβ6 activates TGFβ signaling and drives immune evasion, while negative regulators are often downregulated. Similarly, ITGA5-induced FAK/PI3K/AKT activation in TNBC is associated with poor prognosis, and negative regulators may counteract this pathway. In papillary thyroid cancer, periostin-integrin-FAK-STAT3 signaling promotes tumor growth, highlighting the importance of negative regulation.
Thrombosis and platelet disorders
Platelets require tight regulation of integrin αIIbβ3 to prevent spontaneous aggregation. Negative regulators such as PECAM1 and CD47 help maintain platelets in a resting state. Dysregulation of these pathways can lead to thrombosis or bleeding disorders.
Immune and inflammatory diseases
Negative regulation of integrin activation is crucial for preventing excessive immune cell adhesion and infiltration. In T cells, integrin activation is controlled by negative regulators that prevent autoimmune responses. Defects in these pathways can contribute to inflammatory diseases.
From negative regulation of integrin activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of PTPN2 increase integrin activation? | CRISPR knockout in cell lines; phospho-protein analysis |
| Can point mutation in ITGB1 alter negative regulation? | CRISPR point mutation knock-in; adhesion assays |
| What is the effect of ITGA5 overexpression on tumor growth? | CRISPR overexpression in cancer cells; xenograft |
| How does tagged knock-in of TLN1 affect integrin activation? | CRISPR knock-in with fluorescent tag; live imaging |
| Does knockout of CD47 lead to spontaneous platelet aggregation? | CRISPR knockout in megakaryocytes; platelet function tests |
| Can negative regulators be targeted to enhance immune response? | CRISPR library screening in immune cells |
How to Study the negative regulation of integrin activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function phenotypes | Identify negative regulators of integrin activation |
| Phosphoproteomics | Phosphorylation changes | Map signaling pathways downstream of negative regulators |
| Live-cell imaging | Integrin conformational dynamics | Visualize activation and inhibition in real time |
| Flow adhesion assay | Cell adhesion strength | Quantify integrin activity in platelets or immune cells |
| Proximity ligation assay | Protein-protein interactions | Detect interactions between integrins and regulators |
| RNA-seq | Transcriptional changes | Identify gene expression programs controlled by negative regulators |
| Western blot | Protein expression and phosphorylation | Validate knockout or overexpression effects |
| Platelet aggregometry | Platelet aggregation | Assess negative regulation in thrombosis models |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify negative regulators of integrin activation by selecting for cells with increased adhesion or activation. This approach has been used to uncover phosphatases and other inhibitory proteins.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics allows quantification of phosphorylation changes on integrin-associated proteins upon modulation of negative regulators, revealing signaling nodes.
Live-cell imaging
Fluorescently tagged integrins and regulators enable real-time visualization of conformational changes and localization, providing insights into the dynamics of negative regulation.
Flow cytometry-based adhesion assays
Measuring cell adhesion to immobilized ligands under flow or static conditions can assess integrin activation states and the impact of negative regulators.
How CRISPR Can Be Used to Study GO:0033624 negative regulation of integrin activation
Knockout
CRISPR knockout of negative regulators such as PTPN2 or CD47 can lead to constitutive integrin activation, providing causal evidence for their role. These models are valuable for studying thrombosis and cancer.
Point Mutation
Introducing point mutations in integrin cytoplasmic tails or regulator active sites can dissect specific residues required for negative regulation, revealing molecular mechanisms.
Knock-in
Knock-in of tagged versions of integrins or regulators (e.g., GFP-tagged TLN1) allows tracking of protein localization and dynamics in live cells, elucidating how negative regulation is spatially controlled.
Overexpression
Overexpression of negative regulators can suppress integrin activation and reduce metastasis in cancer models, offering therapeutic potential.
How EDITGENE Supports negative regulation of integrin activation Research
Researchers studying negative regulation of integrin activation-related genes often need to determine whether a candidate gene is causally involved in maintaining integrin inactivity or whether its modulation can reverse pathological activation. EDITGENE provides comprehensive CRISPR-based services to address these questions with precision and scale.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of integrin activation research.
Frequently Asked Questions About negative regulation of integrin activation
What is negative regulation of integrin activation?
It is any process that stops, prevents, or reduces the frequency, rate, or extent of integrin activation, keeping integrins in a low-affinity state.
What genes are involved in negative regulation of integrin activation?
Key genes include PTPN2, ITGA1, ITGB1, CD47, and PECAM1, among others.
How does negative regulation of integrin activation work?
It involves phosphatases, redox modulators, and direct binding proteins that maintain integrins in an inactive conformation or reverse activating signals.
Why is negative regulation of integrin activation important?
It prevents inappropriate platelet aggregation, immune cell activation, and cancer metastasis.
What diseases are associated with defective negative regulation of integrin activation?
Thrombosis, autoimmune diseases, and cancer progression.
How can I study negative regulation of integrin activation?
Use CRISPR knockout, knock-in, overexpression models, phosphoproteomics, and adhesion assays.
What is the role of PTPN2 in integrin activation?
PTPN2 (TCPTP) dephosphorylates signaling molecules to suppress integrin activation and is a key negative regulator.
Can CRISPR screens identify new negative regulators?
Yes, genome-wide CRISPR knockout screens with adhesion-based selection can uncover novel negative regulators.
What is the GO ID for negative regulation of integrin activation?
GO:0033624.
How does EDITGENE support research on this topic?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services tailored to integrin regulation studies.
Conclusion
Negative regulation of integrin activation (GO:0033624) is a critical biological process that maintains cellular adhesion in check, preventing pathological thrombosis, immune dysregulation, and cancer progression. Understanding its molecular players and mechanisms offers promising therapeutic avenues. EDITGENE's advanced CRISPR services empower researchers to dissect these pathways with precision and translate findings into new treatments.
References
- 1. Smith-Garvin JE et al.. 2009. T cell activation.. Annu Rev Immunol 27:591-619 PMID: 19132916
- 2. Bagati A et al.. 2021. Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer.. Cancer Cell 39(1):54-67.e9 PMID: 33385331
- 3. Zhang C et al.. 2024. ZNF460-mediated circRPPH1 promotes TNBC progression through ITGA5-induced FAK/PI3K/AKT activation in a ceRNA manner.. Mol Cancer 23(1):33 PMID: 38355583
- 4. Jin X et al.. 2024. Cancer-associated fibroblast-derived periostin promotes papillary thyroid tumor growth through integrin-FAK-STAT3 signaling.. Theranostics 14(7):3014-3028 PMID: 38773979
- 5. Stefanini L et al.. 2018. Negative regulators of platelet activation and adhesion.. J Thromb Haemost 16(2):220-230 PMID: 29193689
- 6. Pouwels J et al.. 2012. Negative regulators of integrin activity.. J Cell Sci 125(Pt 14):3271-80 PMID: 22822081
- 7. Mattila E et al.. 2005. Negative regulation of EGFR signalling through integrin-alpha1beta1-mediated activation of protein tyrosine phosphatase TCPTP.. Nat Cell Biol 7(1):78-85 PMID: 15592458
- 8. Buricchi F et al.. 2007. Redox regulation of ephrin/integrin cross-talk.. Cell Adh Migr 1(1):33-42 PMID: 19262085
